
	Where results make sense

Topic: Ranbaxy Laboratories

Related Topics

Jet Propulsion Laboratory

Los Alamos National Laboratory

Lawrence Livermore National Laboratory

Bell Laboratories

Lawrence Berkeley National Laboratory

Argonne National Laboratory

Bell Telephone Laboratories

National Physical Laboratory

Abbott Laboratories

The Oak Ridge National Laboratory

Cavendish Laboratory

medical laboratories

In the News (Fri 17 Feb 12)

EXECUTIVE POWER

Iran

ANALYSIS

Pakistan

Family compact

	RANBAXY LABORATORIES LIMITED (Site not responding. Last check: 2007-11-05)
		Ranbaxy’ s global sales have grown at a CAGR of 20% over the last decade and it is now the largest Indian pharmaceutical company in terms of revenues.
		By 2004, Ranbaxy’ s global sales are expected to nearly double to Rs48b and profits would spike by a CAGR of 41% to Rs6.7b.
		According to the management, Ranbaxy has filed for 4 ANDA’s this quarter taking the cumulative tally to 82 and has received approval for 2, taking the cumulative tally of approved drugs to 55.
	www.naviamarkets.com /research/Ranbaxyq3cy02.htm (387 words)

	Ranbaxy Laboratories Limited - Wikipedia
		WÃ¤hle â Ranbaxy Laboratories Limited suchen â um nach Ranbaxy Laboratories Limited zu suchen.
		Falls Du diese Seite soeben erstellt hast, kann es sein, dass die Aktualisierung der Datenbank verzÃ¶gert wurde.
		Ein WÃ¶rterbucheintrag zu Ranbaxy Laboratories Limited hat seinen Platz im Wiktionary ( Wiktionary).
	de.wikipedia.org /wiki/Ranbaxy_Laboratories_Limited (142 words)

	RANBAXY : Newsroom -> Press Releases (Site not responding. Last check: 2007-11-05)
		Ranbaxy Laboratories Limited (Ranbaxy) announced the launch of its brand, Forzest (Tadalafil) in India.
		Ranbaxy Laboratories Limited, India's largest pharmaceutical company, manufactures and markets branded generic pharmaceuticals and Active Pharmaceutical Ingredients.
		Ranbaxy's continued focus on RandD has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research.
	www.ranbaxy.com /newsroom/pressrelease_det.asp?sno=150 (321 words)

	Opinion & Analysis
		Ranbaxy Laboratories reported a 24.3 per cent dip in its profit before exceptionals and tax last quarter, despite a 28.2 per cent increase in sales.
		Ranbaxy’s domestic sales growth at 4.2 per cent was broadly in line with the market.
		Ranbaxy expects sales growth to be in the mid teens in 2005, which means earnings growth could well be in single-digits.
	www.business-standard.com /common/storypage.php?hpFlag=Y&chklogin=N&autono=178506&leftnm=lmnu5&lselect=0&leftindx=5 (894 words)

	Ranbaxy Q1 global sales increase by 18 per cent
		The board of directors of Ranbaxy Laboratories Limited at their meeting held recently, approved the audited accounts for the year ended December 31, 2003 and the unaudited results for the quarter ended March 31, 2004.
		Ranbaxy Laboratories Limited and subsidiaries for the year ended December 31, 2003, recorded consolidated sales of Rs 45,301 million (USD 972 million), registering a growth of 22 per cent.
		Ranbaxy Laboratories Limited and subsidiaries for the quarter ended March 31, 2004, recorded consolidated sales of Rs 13,079 million (USD 290 million), registering a growth of 18 per cent.
	www.expresspharmapulse.com /story.php?&idno=504 (1141 words)

	Torpharm v. ranbaxy
		Ranbaxy nonetheless maintains that the nonobviousness inquiry is here foreclosed, due to TorPharm's "acquiescence" in the examiner's section 103 rejection during prosecution.
		However, Ranbaxy's argument blurs the distinction between claims and limitations : patentability is assessed for the former, not the latter.
		Although Ranbaxy's acquiescence argument thus fails, we do not mean to say that an acquiescence theory may never be invoked in the patentability inquiry.
	www.ll.georgetown.edu /federal/judicial/fed/opinions/02opinions/02-1590.html (4294 words)

	[No title]
		Although Ranbaxy was the first to file an abbreviated new drug application (ANDA) with a patent challenge, it has not been sued by Roche, the spokesperson added.
		Ranbaxy recently received FDA approval for Ganciclovir capsules- 250 and 500 mg dosages.
		Ranbaxy’s generic version generated an annual revenue of around $115 million in the first year of launch and captured a majority of the market for anti-infective drug cefuroxime axetil in the
	www.paladinvest.com /pifiles/Pfizer'sLipitorChallenge082503.htm (468 words)

	The Financial Express: Corporate
		Ranbaxy also plans to enter product segments like ophthalmic preparations, anti-cancer drugs, inhalers, aerosols and paediatric preparations and will offer a range of products.
		Ranbaxy’s generic division — Rexstar — has major products like ‘inj Ranbiotic’ range (gentamicin sulphate) which has emerged as a major brand in the injectible segment with sales of over Rs 7 crore in the first 68 months.
		Ranbaxy also took the plunge by setting up a specialised generic division by taking over the Rs 10 crore hospital business division of Crosslands.
	www.financialexpress.com /fe20010618/corp12.html (361 words)

	Ranbaxy Pharmaceuticals Inc. - Newsroom
		Dr. Kiran Marthak, Vice-president of Ranbaxy Laboratories Limited, Medical Affairs and Clinical Research, will demonstrate the research findings that imply that the bioavailability of the MOS solution was unaffected by fasting or fed conditions in healthy adult subjects.
		Ranbaxy's Riomet™, launched in February 2004, provides a convenient alternative to the traditional tablet form of metformin, the #1 prescribed treatment for Type 2 diabetes.
		Ranbaxy Pharmaceuticals Inc. ("RPI") based in Jacksonville, Florida, is the wholly owned subsidiary of Ranbaxy Laboratories Limited ("RLL"), India's largest pharmaceutical company.
	www.ranbaxyusa.com /newsroom/04-4-30.htm (522 words)

	TIHE 2003: Ranbaxy Laboratories Limited (Site not responding. Last check: 2007-11-05)
		Ranbaxy Laboratories Limited is Indiaâs largest pharmaceuticals company with a mission to become a research based International Pharmaceuticals Company.
		Ranbaxy manufactures and markets generics, value added branded generics and complex active pharmaceuticals ingredients.
		Ranbaxyâs global operations are spread across the continents with products sold in over 100 countries ground operations in 25 countries, manufacturing facilities in 7 countries with an 8000 strong committed work force.
	www.tihe.iteca.uz /en/2003/oview/72212329 (134 words)

	Schwarz stops Ranbaxy drug
		Ranbaxy is the second Indian pharmaceutical company to suffer a setback to its new drug discovery research programme within the last few weeks.
		Ranbaxy was to receive the full payment of $42 million over a period of five to six years.
		Ranbaxy had initially named the molecule Parvosin, after former Ranbaxy chairman and managing director Parvindar Singh, who died in 1999.
	inhome.rediff.com /money/2004/nov/08ran.htm (416 words)

	Ranbaxy Pharmaceuticals Inc. - Corporate Information
		Ranbaxy Pharmaceuticals Inc. (RPI), and Ranbaxy Laboratories Inc. (RLI), were created to achieve the vision and mission of Ranbaxy Laboratories Limited, its parent company, to become a research based international pharmaceutical company.
		RLI, also a wholly owned subsidiary of Ranbaxy Laboratories Limited, is the branded prescription division in the US market and will expand and grow through our R&D efforts, continued exploration of novel drug delivery systems, licensing activities, mergers and acquisitions.
		Ranbaxy Laboratories Limited is positioned today as the tenth largest* generic pharmaceutical company in the world.
	www.ranbaxyusa.com /corporate (241 words)

	Ranbaxy Laboratories Limited (Site not responding. Last check: 2007-11-05)
		Ranbaxy Laboratories Limited is an Indian company incorporated in 1961.
		It exports its products to over 70 countries with ground operations in 25 and manufacturing facilities in 7 countries.
		In 1998, Ranbaxy entered USA, world's largest pharmaceuticals market.
	www.encyclopedia-1.com /r/ra/ranbaxy_laboratories_limited.html (59 words)

	UK Court Judgement Paves Way for Launch of Clarithromycin by Ranbaxy (Site not responding. Last check: 2007-11-05)
		In making its ruling in favor of Ranbaxy's arguments that the asserted patent was invalid on various grounds, the Court agreed that the specific patent claims asserted by Abbott were invalid and characterized it as “a weak patent.” Abbott were refused leave to appeal.
		The MHRA determined the Ranbaxy formulations to be bio-equivalent and to have the same therapeutic effect as that of the drug, Biaxin (also known as Klaracid) of Abbott.
		Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research.
	www.medicalnewstoday.com /medicalnews.php?newsid=17068&nfid=rssfeeds (485 words)

	Optimizing a Purchase Order Workflow for Ranbaxy Laboratories : Case Study
		Ranbaxy Laboratories is India's largest pharmaceutical company and is rated as one of the leading research-based international pharmaceutical organizations in the world.
		Ranbaxy supplies its products to 70 countries and is truly multi-national in nature, with ground operations in 34 countries and manufacturing facilities in 7 countries.
		Ranbaxy's business process systems are implemented on SAP R/3 with materials management as one of the main business modules.
	www.mindtree.com /clt/cs_ranbaxy.html (415 words)

	www.presstrust.com - Ranbaxy's all Round Performance Boosts Q1 Global Sales by 18% (Site not responding. Last check: 2007-11-05)
		The Board of Directors of Ranbaxy Laboratories Limited at their meeting held today, approved the audited accounts for the year ended December 31, 2003 and the unaudited results for the quarter ended March 31, 2004.
		Ranbaxy's operations in USA clocked sales of USD 104.5 Mn, despite the genericisation of one of its key product.i.e.
		Ranbaxy launched its urology brand, Forzest (Tadalafil), which is the most recently approved prescription medicine for the treatment of Erectile Dysfunction (ED) in men.
	www.presstrust.com /article2034.html (1114 words)

	AEGiS-PRn: Ranbaxy HIV Update - January 2005
		Ranbaxy has met this expectation and has filed two additional ARVs with the U.S. FDA after its first ARV filing in October 2004.
		Ranbaxy is committed to making affordable, bio-equivalent ARVs accessible to HIV/AIDS patients throughout the world, particularly to those who might not otherwise be able to access therapy.
		Ranbaxy Inc., based in Princeton, New Jersey, is a wholly owned subsidiary of Ranbaxy Laboratories Limited ("RLL"), India's largest pharmaceutical company.
	www.aegis.com /news/pr/2005/PR050114.html (663 words)

	RANBAXY PHARMACEUTICALS, INC. v. Apotex
		This case is one of many involving the drug cefuroxime axetil, which is a broad-spectrum antibiotic used to treat conditions such as tonsillitis, sinusitis, and skin infections, and exists in two forms: amorphous and crystalline.
		In the district court, Apotex moved for a preliminary injunction arguing that Ranbaxy’s process, which uses acetic acid rather than any of the specifically claimed solvents, infringed under the doctrine of equivalents.
		As for Ranbaxy’s argument that the ’118 patent surrendered coverage of acetic acid because acetone is of the same polarity and in the prior art, there was considerable dispute among the experts over the proper criteria for determining polarity.
	www.ll.georgetown.edu /federal/judicial/fed/opinions/02opinions/02-1429.html (2337 words)

	Drug Access \| Indian Generic Drug Maker Ranbaxy Laboratories To Launch New Antiretroviral Drug in India - ...
		Ranbaxy Laboratories, India's largest drug maker in terms of sales, on Tuesday launched a new antiretroviral drug, which is a generic formulation of a patented medication made by GlaxoSmithKline,
		The Ranbaxy drug, which is equivalent to GSK's Ziagen, also known as abacavir, will be sold under the brand name Virol in 300 milligram tablets.
		According to a Ranbaxy spokesperson, the drug, which is taken twice a day, will cost about $136 a month, with an Indian market size of approximately $6.3 million.
	www.kaisernetwork.org /daily_reports/rep_index.cfm?DR_ID=15876%0D (180 words)

	CNN.com - Two die in Ranbaxy plant fire - Jun. 12, 2003
		Ranbaxy Laboratories is India's biggest drug maker by sales.
		Ranbaxy said the fire would have no material impact on its business, and production at its six other plants could overcome any shortfall.
		Shares in Ranbaxy are 1.54 percent lower at 689.50 rupees in Thursday morning trade.
	www.cnn.com /2003/BUSINESS/06/12/india.ranbaxy (276 words)

	Ranbaxy Laboratories (Site not responding. Last check: 2007-11-05)
		Ranbaxy Laboratories Limited, a leading pharmaceutical company of India, has a strong element of Corporate Social Responsibility inscribed in its values and its concern for the Society extends well beyond its business motives.
		The company does not view success and achievements in terms of commercial gains only but firmly believes that corporate social responsibility is the key for providing a deep symbiotic relationship that exists between the company and the environment it functions.
		Ranbaxy's firm belief that pro-active corporate citizenship is the need of the hour can be traced back to 1979 with the inception of Ranbaxy Rural Development Trust.
	www.indianngos.com /corporate/ranbaxy (1409 words)

	Ranbaxy Laboratories Limited
		Today, Ranbaxy has a presence in over 40 countries with operations in 24 and manufacturing facilities in 6.
		Arguably, Ranbaxy is the best placed among Indian companies to make the best of opportunities that are coming up in the developed markets.
		Besides, the recent threat of biological and chemical war augurs well for Ranbaxy, having got ciprofloaxcin in its kitty, the patent of which is held by Bayer AG.
	www.karvy.com /corp/ranbaxy/ranq302.htm (471 words)

	Brand sale proceeds may prop up Ranbaxy Laboratories Q1 results
		Ranbaxy's official spokesperson, however, said that the company has no statement to make on either query put forth.
		Ranbaxy had, in late June, categorically stated that it had been "in touch" with Bayer AG for the possiblelicensing of a new drug delivery system (NDDS) for ciprofloxacin.
		Meanwhile, the Delhi-based Ranbaxy Laboratories is also expected to receive US FDA approval for its abbreviated new drug application (ANDA) for enalapril maleate, prescribed for the treatment of hypertension.
	www.financialexpress.com /fe/daily/19990727/fco27026.html (372 words)

	US Federal Circuit vacates injunction against Ranbaxy Laboratories (Site not responding. Last check: 2007-11-05)
		Ranbaxy Pharmaceuticals, appealed a US district court's grant of interim injunction to the Glaxo Group on the ground that Ranbaxy's abbreviated new drug application for cefuroxime axetil was likely to infringe their patent covering the drug.
		On April 19, 1999, Ranbaxy Pharmaceuticals Inc. filed an ANDA1 (Abbreviated New Drug Application) with the FDA seeking approval to market a generic tablet form of cefuroxime axetil in anticipation of the '320 patent's expiration.
		Ranbaxy appealed the district court's grant of the preliminary injunction.
	www.wptn.com /pat_005_vol4is5.htm (695 words)

	Research and Markets - Ranbaxy Laboratories Generics Company Intelligence Report - Printer Friendly
		Headquartered in New Delhi, Ranbaxy Laboratories was established in 1961, becoming a public company in 1973.
		Additionally, Ranbaxy claims to be the only Indian company to be registered in Saudi Arabia.
		Ranbaxy has a number of divisions within India, dealing with all aspects of the company’s business.
	www.researchandmarkets.com /reports/75069/75069.htm (616 words)

	Business Wire: Ranbaxy Laboratories registers 20 percent net profit gain in first half ended September 30
		He noted that the company's new dosage forms plant of Ranbaxy's joint venture in China, Ranbaxy Guangzhou China Limited, was inaugurated in Guangzhou in May, and that sales from locally manufactured products commenced in August after all relevant approvals.
		Ranbaxy Laboratories is the largest Indian pharmaceutical company and has the second highest market share in the domestic market.
		Ranbaxy is a major producer of multisource antibiotics/antibacterials, analgesics, and antiulcerant/gastrointestinal drugs.
	www.findarticles.com /p/articles/mi_m0EIN/is_1995_Oct_27/ai_17448964 (419 words)

	Online media mentions for Ranbaxy
		[excerpt] Ranbaxy Laboratories has been seeking to check rising marketing costs in overseas markets via alliances and it is employing this strategy for one of its...
		[excerpt] Ranbaxy Laboratories is in talks with a German firm for acquisition and is set to buy a brand in the US besides setting up a manufacturing unit in Brazil, a...
		[excerpt] Ranbaxy Laboratories is likely to register an over 20% growth in its turnover for the current financial year that ends December, CEO and Managing Director...
	www.cancer-help.org /corp/Ranbaxy.html (3518 words)

	Indiainfoline.com Ranbaxy Laboratories Ltd (Site not responding. Last check: 2007-11-05)
		Ranbaxy has launched a new initiative called Rextar with 225 field representatives through 12 franchisees to flog these products.
		Ranbaxy is already the second largest generics company in India.
		Ranbaxy has been an underperformer amongst the top Indian companies over the past few months due to various concerns, the most important of which were-
	www.indiainfoline.com /comp/ranb/me421.html (1124 words)

	BUDGET.COM.4 - The Economic Times (Site not responding. Last check: 2007-11-05)
		NEW DELHI: Ranbaxy Labs has received the Drugs Controller General of India’s (DCGI) approval to conduct phase-I clinical trials on two of its new chemical entities (NCEs).
		The DCGI, last week, gave the company nod to start phase-I trials in India on the NCE code named RBx 9841, a likely cure for the condition of overactive bladder, and on another molecule called RBx 9001, which is being developed as a drug for treatment of benign prostate hyperplasia (BPH).
		When contacted, a Ranbaxy official confirmed receiving the regulatory go-ahead for conduct of phase-I trials in India on RBx 9841 and RBx 9001.
	economictimes.indiatimes.com /budgetshow/654840.cms (202 words)

	The Global Leader in News Distribution
		Ranbaxy Laboratories Ltd. (Ranbaxy) and GlaxoSmithKline plc (GSK) today announced that they have entered into a drug discovery and clinical development collaboration covering a wide range of therapeutic areas.
		Several collaborative scenarios are envisioned, with GSK and Ranbaxy leveraging their respective resources and expertise.
		Ranbaxy will be responsible for activities from optimization of a lead compound to generation of a development candidate.
	www.businesswireindia.com /PressRelease.asp?b2mid=4066 (435 words)

Try your search on: Qwika (all wikis)